Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Using spatial RNA-protein profiling to identify ADC targets in LMS

Carlos Torrado • 1 Jun 2026
ASCO 2026
Sarcoma

Carlos Torrado, MD, The University of Texas MD Anderson Cancer Center, explores how spatial RNA-protein profiling could be used to identify antibody-drug conjugate (ADC) targets in leiomyosarcoma (LMS). Key analysis including heterogeneity, co-expression and survival associations revealed several targets, as well as several combination targets. Findings are exploratory and require validation with immunohistochemistry and clinical trials. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

ctDNA monitoring for recurrence in bone and soft tissue sarcoma
0:58
ctDNA monitoring for recurrence in bone and soft tissue sarcoma
Maggie Zhou • 1 Jun 2026
ctDNA improves detection and prognostication of sarcoma recurrence
0:45
ctDNA improves detection and prognostication of sarcoma recurrence
Maggie Zhou • 1 Jun 2026
Sarcoma highlights at ASCO 2026: SARC-041, PEAK, and RINGSIDE
1:00
Sarcoma highlights at ASCO 2026: SARC-041, PEAK, and RINGSIDE
Maggie Zhou • 1 Jun 2026
Afami-cel T-cell therapy outcomes in advanced metastatic synovial sarcoma
1:52
Afami-cel T-cell therapy outcomes in advanced metastatic synovial sarcoma
Margaret von Mehren • 31 May 2026
The content of VJOncology is intended for healthcare professionals